Quantum BioPharma Ltd. Seeks Shareholder Approval for $600K Private Placement

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has announced its intention to seek shareholder approval for a non-brokered private placement of class A multiple voting shares (MVS) aiming to raise up to $600,000. This strategic move is set to be discussed at the company's annual general and special meeting scheduled for September 26, 2025. The offering is anticipated to be fully subscribed by existing MVS holders, with the closing expected around the meeting date, pending approval. The proceeds from this placement are earmarked for general working capital purposes, underscoring the company's commitment to sustaining its operational and developmental activities. All securities issued under this placement will be subject to a four-month-plus-one-day hold period in compliance with Canadian securities laws.

Quantum BioPharma Ltd. is at the forefront of developing innovative biotech solutions aimed at addressing challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company's portfolio includes promising drug candidates in various stages of development, with a particular focus on its lead compound, Lucid-MS. This patented new chemical entity has shown potential in preclinical models to prevent and reverse myelin degradation, a key factor in multiple sclerosis. Additionally, Quantum BioPharma's strategic investments and partnerships, such as its stake in Unbuzzd Wellness Inc. and the development of unbuzzd(TM), reflect its diversified approach to growth and innovation in the biopharmaceutical sector.

For more details on Quantum BioPharma Ltd.'s latest developments and strategic initiatives, interested parties can visit https://ibn.fm/LX2gw. This private placement represents a critical step for Quantum BioPharma as it continues to navigate the complexities of the biopharmaceutical industry, aiming to bring groundbreaking treatments to market while ensuring financial stability and growth.